Go Pro
→ Major Buy Alert Issued for September 30th (From TradeSmith) (Ad)tc pixel Free NDRA Stock Alerts

ENDRA Life Sciences (NDRA) Competitors

ENDRA Life Sciences logo
$5.93 -0.57 (-8.77%)
Closing price 04:00 PM Eastern
Extended Trading
$6.24 +0.32 (+5.31%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NDRA vs. PAVM, ELUT, IINN, QTEX, and ARAY

Should you buy ENDRA Life Sciences stock or one of its competitors? ENDRA Life Sciences's main competitors and comparable companies include PAVmed (PAVM), Elutia (ELUT), Inspira Technologies OXY B.H.N. (IINN), Inspira Technologies OXY B.H.N. (QTEX), and Accuray (ARAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does ENDRA Life Sciences compare to PAVmed?

ENDRA Life Sciences (NASDAQ:NDRA) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

PAVmed has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life SciencesN/AN/A-$7.03M-$6.38N/A
PAVmed$70K443.43$400K-$16.05N/A

ENDRA Life Sciences has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

In the previous week, ENDRA Life Sciences and ENDRA Life Sciences both had 1 articles in the media. ENDRA Life Sciences' average media sentiment score of 0.00 equaled PAVmed'saverage media sentiment score.

Company Overall Sentiment
ENDRA Life Sciences Neutral
PAVmed Neutral

ENDRA Life Sciences presently has a consensus target price of $25.00, suggesting a potential upside of 321.59%. PAVmed has a consensus target price of $56.00, suggesting a potential upside of 1,343.30%. Given PAVmed's higher possible upside, analysts clearly believe PAVmed is more favorable than ENDRA Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
PAVmed
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

ENDRA Life Sciences has a net margin of 0.00% compared to PAVmed's net margin of -10,794.64%. PAVmed's return on equity of -126.43% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ENDRA Life SciencesN/A -246.34% -150.81%
PAVmed -10,794.64%-126.43%-25.49%

1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

PAVmed beats ENDRA Life Sciences on 9 of the 11 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Elutia?

Elutia (NASDAQ:ELUT) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Elutia has a net margin of 426.93% compared to ENDRA Life Sciences' net margin of 0.00%. ENDRA Life Sciences' return on equity of -246.34% beat Elutia's return on equity.

Company Net Margins Return on Equity Return on Assets
Elutia426.93% -407.37% -47.08%
ENDRA Life Sciences N/A -246.34%-150.81%

Elutia has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

74.0% of Elutia shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 17.8% of Elutia shares are held by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Elutia had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 2 mentions for Elutia and 1 mentions for ENDRA Life Sciences. Elutia's average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company Overall Sentiment
Elutia Neutral
ENDRA Life Sciences Neutral

Elutia has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elutia$12.29M2.99$53.38M$0.950.87
ENDRA Life SciencesN/AN/A-$7.03M-$6.38N/A

ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 321.59%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Elutia.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elutia
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Elutia beats ENDRA Life Sciences on 10 of the 14 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Inspira Technologies OXY B.H.N.?

ENDRA Life Sciences (NASDAQ:NDRA) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

ENDRA Life Sciences has higher earnings, but lower revenue than Inspira Technologies OXY B.H.N..

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life SciencesN/AN/A-$7.03M-$6.38N/A
Inspira Technologies OXY B.H.N.$289K95.78-$13.22MN/AN/A

ENDRA Life Sciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market.

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ENDRA Life SciencesN/A -246.34% -150.81%
Inspira Technologies OXY B.H.N. N/A N/A N/A

ENDRA Life Sciences presently has a consensus price target of $25.00, suggesting a potential upside of 321.59%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, equities analysts plainly believe ENDRA Life Sciences is more favorable than Inspira Technologies OXY B.H.N..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Inspira Technologies OXY B.H.N.
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, ENDRA Life Sciences and ENDRA Life Sciences both had 1 articles in the media. ENDRA Life Sciences' average media sentiment score of 0.00 equaled Inspira Technologies OXY B.H.N.'saverage media sentiment score.

Company Overall Sentiment
ENDRA Life Sciences Neutral
Inspira Technologies OXY B.H.N. Neutral

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Inspira Technologies OXY B.H.N. beats ENDRA Life Sciences on 6 of the 10 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Inspira Technologies OXY B.H.N.?

Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Inspira Technologies OXY B.H.N.N/A N/A N/A
ENDRA Life Sciences N/A -246.34%-150.81%

12.7% of Inspira Technologies OXY B.H.N. shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are owned by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Inspira Technologies OXY B.H.N. had 2 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 3 mentions for Inspira Technologies OXY B.H.N. and 1 mentions for ENDRA Life Sciences. Inspira Technologies OXY B.H.N.'s average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company Overall Sentiment
Inspira Technologies OXY B.H.N. Neutral
ENDRA Life Sciences Neutral

ENDRA Life Sciences has lower revenue, but higher earnings than Inspira Technologies OXY B.H.N..

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspira Technologies OXY B.H.N.$289K94.57-$13.22MN/AN/A
ENDRA Life SciencesN/AN/A-$7.03M-$6.38N/A

ENDRA Life Sciences has a consensus price target of $25.00, indicating a potential upside of 321.59%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Inspira Technologies OXY B.H.N..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inspira Technologies OXY B.H.N.
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Inspira Technologies OXY B.H.N. has a beta of 4.24, suggesting that its stock price is 324% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

Summary

Inspira Technologies OXY B.H.N. beats ENDRA Life Sciences on 7 of the 11 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Accuray?

Accuray (NASDAQ:ARAY) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

ENDRA Life Sciences has lower revenue, but higher earnings than Accuray. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accuray$401.95M0.07-$49.19M-$0.40N/A
ENDRA Life SciencesN/AN/A-$7.03M-$6.38N/A

Accuray has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market.

In the previous week, Accuray had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 2 mentions for Accuray and 1 mentions for ENDRA Life Sciences. Accuray's average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company Overall Sentiment
Accuray Neutral
ENDRA Life Sciences Neutral

64.1% of Accuray shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 2.4% of Accuray shares are held by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ENDRA Life Sciences has a net margin of 0.00% compared to Accuray's net margin of -12.24%. Accuray's return on equity of -97.85% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Accuray-12.24% -97.85% -10.82%
ENDRA Life Sciences N/A -246.34%-150.81%

Accuray currently has a consensus price target of $2.00, indicating a potential upside of 796.86%. ENDRA Life Sciences has a consensus price target of $25.00, indicating a potential upside of 321.59%. Given Accuray's higher possible upside, equities analysts plainly believe Accuray is more favorable than ENDRA Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accuray
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Accuray beats ENDRA Life Sciences on 9 of the 14 factors compared between the two stocks.

Get ENDRA Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NDRA vs. The Competition

Export
MetricENDRA Life SciencesHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$8.90M$5.49B$7.26B$13.10B
Dividend YieldN/A1.79%2.52%12.57%
P/E Ratio-0.9325.36274.6925.75
Price / SalesN/A89.55679.2597.61
Price / CashN/A33.0277.8052.76
Price / Book3.095.7410.526.34
Net Income-$7.03M$151.55M$3.49B$360.00M
7 Day Performance11.78%-0.36%-1.08%-0.10%
1 Month Performance30.04%-3.97%-3.39%-3.41%
1 Year Performance23.54%5.74%15.08%5.46%

ENDRA Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NDRA
ENDRA Life Sciences
1.8624 of 5 stars		$5.93
-8.8%		$25.00
+321.6%		+37.0%$8.90MN/AN/A11
PAVM
PAVmed
2.5307 of 5 stars		$3.92
-10.7%		$56.00
+1,328.6%		-69.3%$35.10M$70KN/A90
ELUT
Elutia
1.0057 of 5 stars		$0.80
+1.9%		N/A-18.1%$34.77M$12.29M0.84180
IINN
Inspira Technologies OXY B.H.N.
0.0142 of 5 stars		$0.86
-3.9%		N/A-39.1%$30.74M$289KN/A20
QTEX
Inspira Technologies OXY B.H.N.
0.2542 of 5 stars		$0.85
-1.1%		N/AN/A$30.74M$290KN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NDRA) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel